A common guideline created through continuous discussions between companies and government regulatory agencies in the United States, Europe, and Japan since 1990 to aim for drug approval based on the same criteria worldwide, in order to address unnecessary repetition of clinical trials and waste of time in the import and export of pharmaceuticals due to different regulations on clinical trials and drug approval in each country.
Global Training Hub for Biomanufacturing